SGLT2抑制剂改善心衰健康状况的种族差异:三项试验患者层面荟萃分析
该研究合并DEFINE-HF、PRESERVED-HF与CHIEF-HF三项美国随机试验的患者层面数据,分析935例自述黑人或白人患者。12周时SGLT2抑制剂较安慰剂使KCCQ临床汇总评分在白人提高4.0分、黑人提高4.7分,种族与治疗交互作用不显著(P=0.76),提示获益一致。
要点
- SGLT2抑制剂改善心衰患者12周健康状况,黑人与白人获益一致
- 白人KCCQ临床汇总评分提高4.0分,黑人提高4.7分
- 种族与治疗交互作用无统计学意义(P=0.76)
核心结论
- SGLT2抑制剂治疗使黑人与白人射血分数降低或保留心衰患者的健康状况均获得一致且显著的改善。
研究设计与样本
- 三项美国随机对照试验(DEFINE-HF n=263、PRESERVED-HF n=324、CHIEF-HF n=448)的患者层面数据合并分析。
- 1035例参与者中选取自述黑人和白人且有完整信息者,最终分析队列935例,其中黑人236例(25%),接受SGLT2抑制剂者469例(50.2%)。
- 主要终点为12周KCCQ临床汇总评分变化,采用多变量线性回归调整试验、基线KCCQ(限制性立方样条)、种族与治疗,并检验种族与治疗交互作用。
主要发现
- 12周时SGLT2抑制剂较安慰剂使白人KCCQ临床汇总评分提高4.0分(95%CI 1.7-6.3;P=0.0007)。
- 12周时SGLT2抑制剂较安慰剂使黑人KCCQ临床汇总评分提高4.7分(95%CI 0.7-8.7;P=0.02)。
- 种族与治疗的交互作用无统计学意义(P=0.76),其他KCCQ量表结果相似。
临床怎么用
- 对黑人与白人慢性心衰患者,均可预期SGLT2抑制剂在12周内带来约4分的KCCQ临床汇总评分改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health status outcomes, including symptoms, function, and quality of life, are worse for Black compared with White patients with heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular mortality and improve health status in patients with heart failure, but whether the health status benefit of SGLT2is is similar across races is not established. The objective of this study was to compare the treatment effect of SGLT2is (versus placebo) on health status for Black compared with White patients with heart failure. METHODS: We combined patient-level data from 3 randomized clinical trials of SGLT2is: DEFINE-HF (Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure; n=263), PRESERVED-HF (Dapagliflozin in Preserved Ejection Fraction Heart Failure; n=324), and CHIEF-HF (A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure; n=448). These 3 United States-based trials enrolled a substantial proportion of Black patients, and each used the Kansas City Cardiomyopathy Questionnaire (KCCQ) to measure health status at baseline and after 12 weeks of treatment. Among 1035 total participants, selecting self-identified Black and White patients with complete information yielded a final analytic cohort of 935 patients. The primary endpoint was KCCQ Clinical Summary score. Twelve-week change in KCCQ with SGLT2is versus placebo was compared between Black and White patients by testing the interaction between race and treatment using multivariable linear regression models adjusted for trial, baseline KCCQ (as a restricted cubic spline), race, and treatment. The data that support the findings of this study are available from the corresponding author upon reasonable request. RESULTS: Among 935 participants, 236 (25%) self-identified as Black, and 469 (50.2%) were treated with an SGLT2i. Treatment with an SGLT2i, compared with placebo, resulted in KCCQ Clinical Summary score improvements at 12 weeks of +4.0 points (95% CI, 1.7-6.3; P=0.0007) in White patients and +4.7 points (95% CI, 0.7-8.7; P=0.02) in Black patients, with no significant interaction by race and treatment (P=0.76). Other KCCQ scales showed similar results. CONCLUSIONS: Treatment with an SGLT2i resulted in consistent and significant improvements in health status for both Black and White patients with heart failure.
引用
- Gupta, Spertus, Birmingham, et al. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials. Circulation. 2023. PMID: 37191040. doi:10.1161/CIRCULATIONAHA.122.063263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。